Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ESCITALOPRAM

All products: general benefit

Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable

  • Citalopram (Celexa): general benefit, Not a benefit
  • Fluoxetine (Prozac): general benefit, Not a benefit
  • Fluvoxamine (Luvox): general benefit
  • Paroxetine (Paxil): general benefit, Not a benefit
  • Sertraline (Zoloft): general benefit
  • Amitriptyline (Elavil): general benefit

17 more in the class list below

Cipralex · DIN 02263254 · 20mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Cipralex (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Cipralex · DIN 02263254 Manufacturer: Lundbeck Canada Inc.; listing date 2008-11-04 Health Canada: Marketed since 2005-02-14 · brand CIPRALEX -20MG · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 20 MG · company Lundbeck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3310 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74864 · Verify on the e-Formulary ↗ (DIN 02263254)

Source record
DIN 02263254: Cipralex Raw flags: sec3=Y Item: 281604119; group id 460; item number 1153; lccId None; manufacturer id VLH Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.5438; ministry $0.3310 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02263254 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74864
Interchangeable products
Ach-Escitalopram · DIN 02434660 · $0.3310 Apo-Escitalopram · DIN 02295024 · $0.3310 Auro-Escitalopram · DIN 02397374 · $0.3310 Escitalopram · DIN 02429047 · $0.3310 Escitalopram · DIN 02430126 · $0.3310 Jamp Escitalopram · DIN 02508907 · $0.3310 Jamp-Escitalopram · DIN 02429799 · $0.3310 M-Escitalopram · DIN 02471426 · $0.3310 Mar-Escitalopram · DIN 02423502 · $0.3310 Mint-Escitalopram · DIN 02407434 · $0.3310 Mylan-Escitalopram · DIN 02309475 · $0.3310 NRA-Escitalopram · DIN 02476878 · $0.3310 Natco-Escitalopram · DIN 02554933 · $0.3310 PMS-Escitalopram · DIN 02469251 · $0.3310 Ran-Escitalopram · DIN 02385503 · $0.3310 Sandoz Escitalopram · DIN 02364085 · $0.3310 Teva-Escitalopram · DIN 02318202 · $0.3310
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

PAROXETINE HCL

· 47 products · Off-Formulary Interchangeable, not an ODB benefit (16), General benefit (31) · strengths: 10mg, 20mg, 30mg · Tab

SERTRALINE HCL

· 49 products · General benefit · strengths: 25mg, 50mg, 100mg · Cap

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CIPRALEX (escitalopram oxalate) is indicated in adults for: • the symptomatic relief of Major Depressive Disorder (MDD). The efficacy of CIPRALEX in maintaining an antidepressant response, in patients with major depressive disorder who responded during an 8-week, acute-treatment phase while taking CIPRALEX and were then observed for relapse during a period of up to 36 weeks, was demonstrated in a placebo-controlled trial (see 14.1 Clinical Trial by Indication, Major Depressive Disorder (MDD)). • the symptomatic relief of anxiety causing clinically significant distress in patients with Generalized Anxiety Disorder (GAD). The efficacy of CIPRALEX in maintaining anxiolytic response for at least 6 months in patients with GAD was demonstrated in a long-term placebo-controlled trial (in patients who had initially responded to CIPRALEX during a 12-week open-label phase. • the symptomatic relief of obsessive-compulsive disorder (OCD). The obsessions and compulsions must be experienced as intrusive, markedly distressing, time consuming or interfering significantly w… https://pdf.hres.ca/dpd_pm/00072474.PDF PM date: DEC 24, 2004 Source product: CIPRALEX -10MG; DIN 02263238; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.